Torrent Pharma seeks JB Pharma payoff through cost cuts, pruning and cross-selling

Torrent Pharmaceuticals has begun laying the groundwork for extracting value from its Rs.25,700-crore acquisition of JB Pharma, with management signalling that the first wave of gains will come from cost rationalisation, while meaningful revenue synergies are likely to emerge only after the legal merger is consummated.

The company acquired a 48.8 percent controlling stake in PE firm KKR-controlled JB Pharma in January 2026 and plans to absorb the remaining 51.2 percent through a share-swap merger, under which Torrent will issue 51 shares for every 100 JB Pharma shares.

The scheme has received shareholder approvals and is awaiting final National Company Law Tribunal (NCLT) sanction.

In his message to shareholders, Managing Director Aman Mehta described the acquisition as a “transformational step” that “enhances our scale in India, broadens our therapeutic portfolio, deepens our presence in chronic therapies, and strengthens our international footprint.” He added that the proposed merger would create “meaningful opportunities to create value through complementary strengths and wider market reach.”

Brokerage Equirus estimates that Torrent expects to generate Rs. 450 crore of cost synergies, equivalent to roughly 10 percent of JB Pharma’s trailing revenue base. The benefits will be staggered, with around 20 percent accruing in the first year, 60 percent in the second year after the merger, and the balance in the third year.

Importantly, Torrent has already started pruning businesses that do not fit its profitability framework. According to Equirus, the company has discontinued JB Pharma’s low-margin trade generics business as part of efforts to align JB Pharma’s margin profile with Torrent’s own.

“As Torrent onboarded JB Pharma, it began pruning low-margin business (discontinuing trade generics) to align JB Pharma's margin profile with its own,” Equirus said in its annual report analysis.

Torrent management has repeatedly said they are evaluating revenue-side cross-selling synergies, but only after post-merger. Mehta said the merger creates “meaningful opportunities through complementary strengths, wider market reach, and enhanced capabilities across key therapeutic segments.”

The logic is straightforward. The combined entity will have a field force of around 9,300 medical representatives, compared with Torrent’s standalone 7,000-plus. That expanded reach could allow Torrent’s brands to be pushed through JB Pharma’s doctor network and vice versa.

The merger also creates a stronger chronic therapy franchise. Together, the companies now rank fifth in the Indian Pharmaceutical Market, with leadership positions across cardiac, gastroenterology, central nervous system and dermatology therapies. The chronic and sub-chronic portfolio accounts for about 75 percent of domestic revenue, giving Torrent a larger prescription base to cross-sell products.

Beyond sales and procurement savings, the acquisition offers several additional strategic benefits.

First, it expands Torrent’s presence in therapeutic areas where JB Pharma is strong, particularly ophthalmology and gynaecology. Second, it provides access to JB Pharma’s contract development and manufacturing (CDMO) business, especially its medicated lozenges franchise. Third, it strengthens Torrent’s international footprint through JB Pharma’s established positions in Russia and South Africa.

The annual report highlighted that the acquisition would “enhance healthcare access” through a broader product offering and wider market reach. Torrent also said the transaction would help create a “future-ready, diversified healthcare platform” by combining JB Pharma’s chronic-care strengths with Torrent’s scale and execution capabilities.

The deal is not without financial costs. Torrent funded the acquisition largely through Rs.11,000 crore of borrowings at 7.15 percent, which Equirus estimates will increase interest costs by around Rs.800 crore in FY27. In addition, acquired brands and trademarks worth about Rs.20,800 crore will lead to annual amortisation charges of roughly Rs.1450 crore for the next 15 years.

Still, management appears convinced the long-term benefits outweigh the near-term earnings drag. As Aman Mehta told shareholders, “this acquisition not only strengthens our core but also acts as a catalyst, accelerating our journey towards long-term, sustainable growth.”